DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lilotomab
Lilotomab
Understanding Understanding Non-Hodgkin Non-Hodgkin Lymphoma Lymphoma This Patient Guide Is Supported Through Unrestricted Educational Grants From
Journal of Cancer Biology and Therapeutics
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
2017 Immuno-Oncology Medicines in Development
The Two Tontti Tudiul Lui Hi Ha Unit
Combination of 177Lu‐Lilotomab with Rituximab Significantly Improves The
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
Vedlegg INSPIRE:Lungekreft 1 Virkestoff, Type Behandling, Tilordning
Understanding Non-Hodgkin Lymphoma
1 Title: Biodistribution and Dosimetry Results from a Phase 1 Trial of 177Lu
United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
2018 Medicines in Development for Cancer
(INN) for Biological and Biotechnological Substances
Total Tumor Uptake and Absorbed Dose of 177Lu- Lilotomab Satetraxetan in a First in Human Trial for Relapsed Non-Hodgkin Lymphoma - Are We Hitting the Target?
Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininkas
Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug 8 October 2020
Top View
Biodistribution and Dosimetry Results from a Phase 1 Trial of 177Lu-Lilotomab Satetraxetan
A61K9/51 (2006.01) — with International Search Report (Art
CD20 and CD37 Antibodies Synergize to Activate Complement by Fc-Mediated Ferrata Storti Foundation Clustering
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
Annual Report 2020 ANNUAL REPORT 2020 L NORDIC NANOVECTOR 3
Omdirigert Skriverdokument for Eksternt Skrivebord
2020 Medicines in Development ꟷ Cancer
Download PDF Here
Hodgkin Lymphoma Marion Masitsa Malenge
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
Poster-Aacr 2018-Boston-Usa.Pdf
A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
The Therapeutic Effectiveness of 177Lu-Lilotomab in B-Cell Non- Hodgkin Lymphoma Involves Modulation of G2/M Cell Cycle Arrest
Myelosuppression in Patients Treated with 177Lutetium-Lilotomab Satetraxetan Can Be Predicted with Absorbed Dose to the Red Marrow As the Only Variable
(INN) for Biological and Biotechnological Substances
Phase 1/2A Study of Lu-Lilotomab Satetraxetan in Relapsed/Refractory
177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non
Updated Results of a Phase I/Ii Study of 177Lu-Lilotomab
14-ICML Accepted Abstracts
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri